Home / Blog

Black & White writing

Research peptide writing from the inside.

Honest, plain-English writing on the UK research-peptide market. How to spot fakes, how to read an HPLC report, compound deep-dives, what actually changes when MHRA guidance shifts. Written by Joe, founder. Updated whenever something material changes - not on a content schedule.

Industry reality

Trust & suppliers

Lab literacy

HPLC & reading reports

Compound deep-dives

Single-peptide writing

UK regulation

MHRA, customs, MoDA
Cornerstone reference

The A-Z Peptide Bible: UK Research Reference

By Joe, founder · Updated 29 April 2026 · ~12 min read

A free, single-page reference manual for 50+ research peptides A to Z. Each entry has sequence, half-life, mechanism, stability profile and a primary literature citation. Maintained by us, no signup, no paywall.

Industry reality

Trust signals, supplier vetting, what actually goes wrong. The honest writing the rest of the market avoids.

Industry reality

How to spot a fake research peptide supplier (UK 2026)

By Joe · 29 April 2026 · ~9 min read

A 12-point checklist for vetting any UK research-peptide supplier, written by a UK supplier. Includes us scoring ourselves transparently against the same criteria.

Lab literacy

Building the technical fluency to evaluate any supplier yourself.

Lab literacy

How to read a Janoshik HPLC report: line by line

By Joe · 29 April 2026 · ~7 min read

An annotated walkthrough of a real Janoshik Certificate of Analysis. What every line means, how to verify the batch independently, and how to spot a fake report.

Compound deep-dives

Single-peptide writing, drawn from the published literature.

Compound deep-dive

Retatrutide: the triple-receptor agonist

By Joe · 6 May 2026 · ~10 min read

A 39-amino-acid synthetic peptide developed by Eli Lilly that activates three receptors at once: GIP, GLP-1, and glucagon. The first trinity agonist to publish a full Phase 2 dataset (Jastreboff NEJM 2023). 24.2 percent body-weight reduction at 48 weeks. TRIUMPH Phase 3 in progress.

 Compound deep-dive

Tirzepatide: the dual GIP and GLP-1 receptor agonist

By Joe · 6 May 2026 · ~10 min read

A 39-amino-acid synthetic peptide developed by Eli Lilly that simultaneously activates both incretin receptors. The first twincretin to reach late-stage development. Beat semaglutide on every endpoint of SURPASS-2. Sits as the most-discussed compound in metabolic research right now, and the most actively counterfeited.

 Compound deep-dive

BPC-157: the most-researched peptide in the catalogue

By Joe · 6 May 2026 · ~9 min read

A 15-amino-acid fragment derived from a body-protective compound first isolated from human gastric juice. Characterised at the University of Zagreb from 1991 onwards. Over 200 peer-reviewed papers. The unusual property that put it on the map: it survives gastric acid.

 Compound deep-dive

Selank: the underrated Russian anxiolytic peptide

By Joe · 2 May 2026 · ~9 min read

A synthetic tuftsin analogue developed at the Russian Academy of Medical Sciences in the 1990s. Thirty years of literature on tuftsin-family receptor binding, GABAergic modulation, BDNF effects and the intranasal route - almost completely absent from Western research conversations.

 Compound deep-dive

GHK-Cu explained: the blue copper peptide

By Joe · 1 May 2026 · ~8 min read

The copper-bound tripeptide first isolated by Pickart in 1973. Why it's vivid cobalt blue, what 50 years of literature says, how to verify a batch is real, and the supplier red flags almost no buyer knows to check.

 Compound deep-dive

Semaglutide vs Retatrutide: single vs triple receptor agonist

Updated 26 April 2026 · ~6 min read

Side-by-side comparison of the two most-cited GLP-1-class compounds in current metabolic-research literature. Receptor pharmacology, half-life, lab handling.

 Compound deep-dive

GHK-Cu vs BPC-157: copper tripeptide vs pentadecapeptide

Updated 26 April 2026 · ~5 min read

Two of the most widely cited regenerative-research peptides with very different chemistry. Mechanism, stability, selection criteria.

 Compound deep-dive

CJC-1295 (DAC) vs Sermorelin: extended vs original GHRH

Updated 26 April 2026 · ~5 min read

Both are GHRH receptor agonists, but they differ dramatically in serum half-life. Why DAC modification changes everything.

UK regulation

MHRA framework, Misuse of Drugs Act position, customs reality.

UK regulation

UK legality of research peptides: the framework explained

Reference page · ~8 min read

The Misuse of Drugs Act 1971, MHRA marketing authorisation, and the research-reagent supply category. Plain-English explanation of where research peptides actually sit in UK law.

New post about once a month

No marketing spam. Just a note when something material gets added or updated.

One email per new post, ~monthly cadence. Unsubscribe in one click. We never share or sell email addresses.